Phillip Schwartz - Jan 1, 2022 Form 3 Insider Report for Entera Bio Ltd. (ENTX)

Role
President of R&D, Director
Signature
/s/ Dana Yaacov-Garbeli, Attorney-in-fact
Stock symbol
ENTX
Transactions as of
Jan 1, 2022
Transactions value $
$0
Form type
3
Date filed
1/11/2022, 03:04 PM
Next filing
Jan 24, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ENTX Ordinary Shares, par value NIS 0.0000769 per share 597K Jan 1, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ENTX Stock Option (right to buy) Jan 1, 2022 Ordinary Shares, par value NIS 0.0000769 per share 358K $6.31 Direct F1
holding ENTX Stock Option (right to buy) Jan 1, 2022 Ordinary Shares, par value NIS 0.0000769 per share 100K $3.15 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options vested ratably on a quarterly basis over a four-year period commencing on February 23, 2018.
F2 The options vest over a four-year period that commenced on April 21, 2021, with 25% of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining three-year period.

Remarks:

See Exhibit 24.1 - Power of Attorney